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Short Title: Perspectives and information needs on predictive testing in rheumatoid 
arthritis 
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Abstract 
Objective: Little is known about the experiences, values and needs of people without 
arthritis who undergo predictive biomarker testing for the development of rheumatoid 
arthritis (RA). Our study aimed to explore the perspectives of these individuals and 
describe their information needs. 
Methods: A qualitative, multicenter interview study with a thematic analysis was 
conducted in Austria, Germany and the UK. Individuals who underwent predictive 
biomarker testing for RA and had a positive test result, but no diagnosis of any 
inflammatory joint disease, were interviewed. Participants included patients with 
arthralgia and asymptomatic individuals. Information and education needs were 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
developed from the qualitative codes and themes using the Arthritis Educational Needs 
Assessment Tool (ENAT) as a frame of reference. 
Results: Thematic saturation was reached in 34 individuals (76% female; 24 [71%] 
with arthralgia and 10 [29%] asymptomatic individuals). Thirty-seven codes were 
summarized into four themes, namely (i) decision making around whether to undergo 
initial predictive testing, (ii) willingness to consider further predictive tests and/or (iii) 
preventive interventions, including medication and (iv) varying reactions after 
receiving a positive test result. Individuals with arthralgia were more likely to be willing 
to take preventive action, undergo further testing, and experience psychological distress 
than asymptomatic individuals. All participants expressed the need for tailored, lay-
understandable information. 
Conclusion: Individuals at risk of RA are currently the subjects of research aimed at 
developing better predictive strategies and preventive approaches. Their perceptions 
and needs should be addressed to inform the future development of interventions 
combined with education. 
 
Significance and Innovations 
 To our knowledge, our study explored for the first time experiences of being 
tested, as well as information and support needs of people with arthralgia and 
asymptomatic individuals who underwent predictive biomarker testing for RA 
and had a positive test result. 
 All individuals expressed the need for tailored, lay-understandable information 
on predictive testing. Most of them emphasized the advantage of knowing that 
they were at risk for developing RA as early as possible.  
 Individuals with arthralgia were more likely to be willing to take preventive 
action, undergo further testing, and experience psychological distress than 
asymptomatic individuals. 
 As individuals at risk of RA are currently the subjects of research aimed at 
developing better predictive strategies and preventive approaches, their 
perceptions and needs should be addressed to inform the future development of 
interventions combined with education.  
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Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease with an 
incompletely understood etiology. RA is characterized by polyarticular swelling leading 
to pain, stiffness and loss of joint function and affects between 0.3% and 1% of the 
population (1). Delays in diagnosis and treatment are still common and are associated 
with worse outcomes, including irreversible joint destruction, disability, limitations in 
functioning and reduced quality of life (2-5). Early identification of RA patients is thus 
essential to achieve an optimal clinical outcome (6) and has been the target of several 
research initiatives (7). Since RA is commonly preceded by a phase of immunological 
abnormalities including the presence of antibodies to citrullinated proteins (ACPA) and 
low grade inflammation (8-12), future interventions might start even earlier, by 
identifying and treating individuals who are at risk of developing RA (e.g those with a 
first degree relative with RA and patients with clinically suspect arthralgia or 
undifferentiated arthritis) before the development of clinically apparent polyarthritis 
(13, 14). Therefore, researchers have explored predictive testing methods involving 
blood based biomarkers, imaging (e.g. ultrasound and magnetic resonance imaging 
[MRI]), as well as more invasive methods like synovial biopsies (6, 8, 15-20) in the time 
preceding RA. 
Predictive and preventive approaches can lead to the early detection of certain diseases 
with benefits for the people themselves, the health system and its payers, and for 
society as a whole (21, 22). However, there is a risk of over treatment of those receiving 
a false positive test result (13). Although predictive tests have been carried out in a 
range of disease contexts, there is limited research on the perspectives of those who 
undergo such tests (23). Moreover, the tested individuals need to be informed by 
physicians and health professionals about the tests and their purpose, as well as test 
results, potential risk factors and preventive strategies relevant for them. Therefore, 
targeted, person-centered information and communication strategies should be 
developed alongside the predictive tests to explain what it means to be at risk of RA and 
the potential benefits and risks of early intervention as well as preventative strategies. 
This may improve the self-efficacy and health literacy of individuals who are at risk of 
developing RA, raise awareness of (future) preventive interventions, reduce potential 
delays in help-seeking for early symptoms, and facilitate improved clinical outcomes. In 
recent years, a great number of putative predictive tests in the context of RA have been 
carried out in numerous cohort studies and as part of extended preventive medical 
check-ups (24, 25). Nevertheless, little is known about the needs, values and beliefs of 
individuals who undergo predictive testing for RA, and are informed about a positive 
biomarker test result. In their recent work, Sparks et al. (14, 26) showed that 
individuals receiving personalized risk disclosure and education were more motivated 
to change their health behavior than individuals who received standard education about 
RA. However, the experiences of being tested, as well as information and support needs 
of individuals who undergo predictive testing for RA have not been described in detail 
yet. 
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The aims of this study were to (i) explore the perspectives of individuals who 
underwent predictive biomarker testing for RA and were informed about a positive test 
result regarding ACPA and/or rheumatoid factor, (ii) find similarities and differences in 
the views of individuals with arthralgia and asymptomatic individuals which might 
represent different levels of risk in the development of RA and (iii) describe the 
information and education needs in both groups. 
 
Participants and Methods 
Design 
A qualitative, multicenter interview study and thematic analysis were conducted, as 
part of the EuroTEAM (Towards Early diagnosis and biomarker validation in Arthritis 
Management) project (27). Information and education needs were developed from the 
codes and themes that emerged out of the qualitative analysis using the Arthritis 
Educational Needs Assessment Tool (ENAT) as a frame of reference (28-30). 
Participants and sample size consideration 
Individuals, ≥ 18 years attending rheumatology centers in Vienna (Austria), Erlangen 
(Germany) and Birmingham (UK) who had predictive biomarker tests for RA with a 
positive test result, but had not received a diagnosis of any inflammatory joint disease, 
were eligible for the present study. Individuals were either referred for testing because 
of symptoms or had a predictive test for RA as part of an extended medical check-up. 
ACPA and rheumatoid factor (RF) were considered positive according to the reference 
values in each center. Participants included both people with arthralgia in at least one 
peripheral joint and asymptomatic individuals. All participants were contacted by 
phone, and appointments for conducting the interview at the participating center were 
made with those wishing to participate. Recruitment continued until thematic 
saturation was reached. Saturation was defined as no new qualitative codes coming up 
in at least ten subsequent interviews (31, 32). In order to determine the number of new 
codes in each interview, data analysis started soon after the first interview and 
proceeded in parallel to data collection (33). 
The study was approved by the Ethics Committee of the Medical University of Vienna 
(EK Number 2174/2013), the Ethics Committee of the University of Erlangen-
Nuernberg (Re.No-87_14B), and the Humber Bridge National Research Ethics 
Committee of Birmingham (REC reference 13/YH/0329). Eligible people were informed 
about the purpose and procedures of the study and gave their oral and written informed 
consents. 
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Data collection 
A semi-structured one-to-one interview was conducted with each participant. Based on 
a review of the qualitative literature exploring public perceptions of predictive tests and 
experiences of being labelled as “at risk” for a chronic disease (34, 35), the research 
team co-developed an English interview guide together with biomarker experts and 
patient research partners (DS, MD). The initial structure of the interview schedule was 
revised and questions were modified as a result of feedback from both groups, to ensure 
that the descriptions of predictive tests were accurate and understandable by a lay 
audience. The interview questions are depicted in Table 1. Health professionals with 
experience in qualitative research data acquisition and/or experiences as principal 
investigators of qualitative studies performed the interviews: EM (female, MSc, 
background in occupational health and health science), MS (female, PhD, occupational 
health and health science), AH (male, MD, PhD, rheumatology), RS (female, PhD, 
psychology) and GS (female, PhD, psychology). All interviews were audio-recorded, 
transcribed verbatim and analysed centrally in Vienna, Austria, by EM with input from 
the local investigators from Erlangen and Birmingham and the patient research 
partners. 
 Table 1 
 
Data analysis 
Qualitative data analysis followed a modified form of thematic analysis (36, 37) and was 
facilitated by using QSR International’s NVivo 10 qualitative data analysis software [43-
45]. The analysis comprised the following steps: firstly, the first author (EM) read 
through the transcripts to gain an overview of the collected data and to become familiar 
with the content. Secondly, the transcripts were divided into meaningful segments of 
data (defined as specific units of text, either a few words or a few sentences with a 
common meaning). In the third step, initial codes (descriptive or conceptual labels), 
such as be shocked/be anxious, get worried and stay calm were assigned to these 
segments. Codes could refer to the main topic of a meaningful segment, but one segment 
could also contain more than one code. In the fourth step, the initial codes were grouped 
into associated higher-level themes. The codes be shocked/be anxious, get worried and 
stay calm were grouped under the higher-level theme varying reactions after receiving a 
positive test result. Thereafter, we compared the codes and themes between individuals 
with arthralgia and asymptomatic individuals for similarities and differences regarding 
the qualitative meaning of a concept and its quantitative frequencies using descriptive 
statistics. Information and education needs were developed based on the qualitative 
codes using the ENAT as a frame of reference (28-30). 
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Rigor and accuracy of the qualitative data analysis 
Several strategies were used to improve and verify the trustworthiness of the 
qualitative data: debriefing notes were recorded after each interview. All local 
investigators who conducted interviews, namely EM and MS in Austria, AH in Germany 
and RS and GS in the UK checked the transcripts against the audiotapes for accuracy. 
After analyzing all interviews, the results were discussed with researchers of all centres 
and reviewed by patient research partners (DS,MD) and a senior researcher (TS) who 
had not been involved in the analysis of the transcripts. Finally, the consolidated criteria 
for reporting qualitative research (COREQ) Checklist (38) was used to ensure the high 
quality of reporting the study results (supplemental table 1). 
 
Results 
Participant characteristics 
Thematic saturation (supplemental table 2) was reached after including 34 individuals 
(76% female; 24 [71%] individuals with arthralgia and 10 [29%] asymptomatic 
individuals). Of these, 15 (44%) participated in Austria, 15 (44%) in Germany and 4 
(12%) in the UK (table 2). 
 Table 2 
 
Codes and higher-level themes 
We extracted 37 codes that were grouped under four higher-level themes, namely (i) 
decision making around whether to undergo initial predictive testing, (ii) willingness to 
consider further predictive tests and/or (iii) preventive interventions, including 
medication and (iv) varying reactions after receiving a positive test result (tables 3 and 
4). 
 Table 3 
 
Similarities between individuals with arthralgia and asymptomatic individuals 
Asymptomatic participants and individuals with arthralgia indicated that being told 
about their risk of developing RA had both, positive aspects (knowing the risk; knowing 
whom to contact if symptoms progressed), as well as negative consequences (having to 
deal with the uncertainty associated with risk information) for them. Regarding positive 
aspects, the majority of participants in this study (32; 94%) were convinced that they 
benefited from knowing their risk status as early as possible. They felt this knowledge 
would enable them to react appropriately if RA related symptoms developed or 
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extended in the future. Furthermore, getting to know the people whom one should 
approach in case of symptom onset or progression, was described as positive: 
If I develop RA, I know that I will get the best possible care here. I know I’ll get very 
quick access to care; and I know the people whom to approach; this will improve 
my outcome. (No. 13, female, age 40, arthralgia, UK) 
After the test I knew, if I develop it I have to react quickly, so that something will be 
done. (No. 4, male, age 52, asymptomatic, Austria) 
Regarding the negative experiences, some participants of our study reported that 
dealing with an imprecise risk without further information, such as information about 
when RA is likely to develop had a negative connotation for them and posed a 
substantial challenge. One male participant described this as follows: 
For me, the best would be to describe the risk in numbers and to know when the 
onset will be. How much will the disease impact on my life? What can I do? How can 
I prevent the onset of the disease? And so on. (...) just to say that it will come 
anytime, is not enough for me. (No. 14, male, age 38, arthralgia, Germany) 
One would have to learn in what way that [test result] is significant. But you hear, 
you have 10 percent risk for something, or 90 percent and the question is, whether 
something can be done. (No. 4, male, age 52, asymptomatic, Austria) 
Differences between individuals with arthralgia and asymptomatic individuals 
Within all four higher-level themes, we found differences between individuals with 
arthralgia and asymptomatic individuals. Regarding the first higher-level theme decision 
making around whether to undergo initial predictive testing, people already suffering 
from pain or stiffness aimed to obtain assurance about causes for their symptoms and to 
receive confirmation that something was wrong with their body, whereas asymptomatic 
individuals were more likely to undergo predictive testing in order to contribute to 
research only.  
Regarding the second higher-level theme willingness to consider further predictive tests, 
individuals with arthralgia were more likely to agree to further predictive tests than 
asymptomatic individuals. Invasive methods such as synovial or lymph node biopsies 
were the areas with the largest difference between both groups: 12 individuals with 
arthralgia (50%) would agree to synovial biopsy compared to only one asymptomatic 
participant (10%). 
I would take it [synovial biopsy] and I would not mind but rather be interested in 
it. I am also not very sensitive to pain so it is no problem at all. (No. 21, female, age 
76, arthralgia, Austria) 
Regarding the third higher-level theme willingness to consider preventive interventions, 
including medication, nine (38%) individuals with arthralgia would agree to take future 
preventive medication under certain conditions, if available, compared to none of the 
asymptomatic individuals. One participants with arthralgia described the circumstances 
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and conditions under which he would be willing to take preventive medication as 
follows: 
Fundamentally positively, whereby you have to consider the side effects. There is 
almost no medicine without any side effect. Nonetheless, when I envision a future 
damage of the body, an early investigation is very useful. (No. 14, male, age 38, 
arthralgia, Germany) 
One asymptomatic participant who would refuse to take any future preventive 
medication articulated the following: 
I would only take medication, if I am sick. In my opinion, chemicals and drugs 
always have side effects and you have to weigh the pros and cons, especially if you 
overdo it and take a whole cocktail of medicine then you are experimenting without 
knowing the outcome. So, medication is for treating already existing disease, not 
for prevention. (No. 25, male, age 57, asymptomatic, Austria) 
Regarding potential non-pharmacological interventions, the majority of the individuals 
with arthralgia (20/24 [83%]) reported that they were willing to consider life-style-
changes to reduce their risk of developing RA compared to only 2/10 (20%) of the 
asymptomatic participants. 
Regarding the fourth higher-level theme varying reactions after receiving a positive  test 
result, asymptomatic partcipants in our study described that they had been able to stay 
calm (8/10 80%] compared to only 4/24 [17%] individuals with arthralgia). In contrast, 
10/24 (42%) individuals with arthralgia reported anxiety and were shocked when they 
were told about the positive test result compared to none of the asymptomatic 
individuals. 
Furthermore, some individuals with arthralgia experienced difficulties in talking about 
being a person at risk and informing their families and friends. One woman talked about 
avoiding unnecessary burden for her loved ones. She said: 
[…] my last question when I left the clinic was how to tell people […]. So that was 
one of my concerns […], the communication of it all and I didn’t want to, even 
though I was  feeling overwhelmed, I didn’t particularly want other people to panic 
and then panic me. (No. 13, female, 40, arthralgia, UK) 
We aimed to assess whether there were differences in views between participants with 
and without a positive family history of RA. Only one asymptomatic participant had a 
family history of RA. Despite the fact that her mother and grandmother had RA, this 
person was not concerned about the positive test result and reported that she was 
unlikely to modify her lifestyle or take future preventive medication. In contrast, people 
with arthralgia and a positive family history in RA reported higher levels of anxiety 
when being informed about the positive test and would modify their life to a greater 
extent. 
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Information and education needs 
All participants in both groups described the need for tailored, lay-understandable 
information to be delivered by health professionals together with the positive test result 
(second-last column of table 3). One participant expressed her experience in the 
following statement: 
It’s important that they don’t use these medical terms when explaining something, 
but trying to explain it by using examples. For them, this is a standard vocabulary, 
but for me this is a foreign word. (No. 6, female, age 52, asymptomatic, Austria) 
Furthermore, the majority of participants in this study missed clear and precise 
statements concerning different possibilities to prevent the onset of the disease. In that 
sense, they were especially interested if and what they could do themselves to reduce 
the risk of RA development. As an example, participant No. 15 (female, age 52, 
arthralgia, Germany) argued: 
The one thing I would be curious about to find out, would be what I can do to stay 
healthy. And there is not much I found out so far. Specific information would help a 
lot. 
The qualitative codes and themes could be linked to all seven sections of the ENAT; 
however, predictive testing has not been part of the ENAT so far (last column of table 3). 
 Table 4 
 
Discussion 
To our knowledge, this is the first study that provides insights about the experiences, 
values and needs of people with arthralgia and asymptomatic individuals who 
underwent predictive testing for RA and had a positive test result. The results from the 
study show that predictive testing raises several ethical issues. All participants were 
informed about their risk of developing RA when receiving the test results. They also 
heard about RA related symptoms that might occur in future and whom to contact if 
such symptoms developed or their current symtoms extended in the future. 
Nevertheless, and in accordance with Cornelis et al. (39), participants of our study 
pointed out that they experienced a negative impact on their emotional well-being and 
that they were not well prepared for a possible positive test result. Participants with 
arthralgia in particular reported that they were frightened and worried. Although they 
had developed strategies to cope with this situation, they indicated that they would 
have preferred additional tailored information and support at the time when they were 
told that they had an elevated risk of developing RA. Clinicians should address the 
information and support needs identified in the current study by further developing 
effective, tailored education to support decision making about whether to take a 
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predictive test and provide guidance and support for understanding and coping with 
test results (14, 40).  
Interestingly, insurance implications were only mentioned by two participants in this 
study; both were critical of the fact that preventive stategies were not paid by their 
health insurances. Moreover, ethical issues, such as confidentiality of the given risk 
information, were not explicitly mentioned by any of the participants. Participants 
might have assumed that these tests fall under the legal requirements of data protection 
regarding health data and as such are strictly confidential. In contrast to that, some 
people with arthralgia had chosen not to talk about their risk for developing RA with 
their families and friends in order not to frighten them. They decided to wait for tests 
with a higher degree of predictive accuracy before informing their loved ones. In two 
recent studies, researchers found that “at risk” individuals had a strong preference for a 
predictive test that would rule future RA in/out with absolute certainty (23, 41). 
Despite the negative issues raised by the participants, very few (two) of them regretted 
they had been tested. However, arthralgia patients did not take an active decision to 
engage in predictive testing, but rather a decision to seek medical help for their 
arthralgia and the testing was a consequence of that. This knowledge might be of great 
importance when testing on a large scale and developing personalized, innovative 
preventive strategies in the next few years. Even if there is currently limited evidence to 
support both population-based screening programmes and personalized individual 
predictive tests, the scenario may change significantly in the future (22, 42). The desire 
to ensure that testing programmes do not cause more harm than good, has led to a 
considerable body of research on the psychosocial impact of predictive testing in adults, 
for a range of conditions including hereditary breast and ovarian cancer and 
Huntington's disease (43). In this sense, predictive testing for RA can also be seen as an 
important public health issue with benefits for at-risk individuals themselves, clinicians, 
researchers and the health system, if it were to be introduced into clinical practice and 
public health in a responsible manner combined with a tailored information for all the 
persons concerned.  
As the aim of our qualitative study was to explore a wide range of experiences, 
differences regarding the time between tests and the interviews were considered to be 
an advantage. Even if the time between being informed about the personal risk and 
being interviewed differed among the participants, the majority emphasized the 
advantage of knowing about their risk for developing RA. Being aware of their risk 
status would allow them to react appropriately and rapidly, if symptoms such as 
synovial joint swelling occurred. In accordance with the study results of Stack and 
colleagues [23], exploring the perceptions of risk and predictive testing held by the first-
degree relatives of patients with RA, some participants suggested that ongoing support 
by health professionals should be offered for those who have additional questions 
regarding their personal risk. 
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Another frequent topic was the question of effective preventive strategies which would 
be important to prevent the onset of RA. While some risk factors for RA related to 
lifestyle have already been identified (e.g. smoking), it has not yet been fully clarified 
how most of the identified risk factors influence RA-related autoimmunity. 
Furthermore, risk factors may differ between individuals or groups of individuals, and 
be influenced by gender and other personal and environmental factors (44). 
Participants in our study asked for activities which they could implement in daily life to 
reduce the risk of RA onset. Therefore, they need to be provided with more information 
about these present uncertainties. Individuals at risk need to know that there is still 
more data needed before detailed environmental risk factor modification and lifestyle 
changes, other than smoking cessation, can be recommended. Meanwhile, we could at 
least ensure that people at risk recognize the symptoms of disease 
development/progression and know where to go if such symptoms were to occur (4). 
European guidelines for the management of RA (45, 46) highlight the importance of 
early treatment. 
The strength of this study is that it represents a comprehensive exploration of the 
experiences, values and needs of people who underwent predictive testing for RA and 
had a positive test result by reaching data saturation in three centers/countries. 
However, one limitation of our study was the difficulty to recruit asymptomatic 
individuals with a positive test result. A selection bias might have occurred since people 
who take part in an extended preventive health exam might be more interested in 
additional data about their own health, than the average population. Furthermore, 
women were over-represented in our study, as women were found to be more likely to 
sign up for health check-ups than men (47). 
To conclude, participants showed large differences in views about predictive testing in 
the context of RA risk and offered specific suggestions that should be incorporated into 
service design and delivery in the context of future predictive testing programmes. 
These findings may also be relevant to prediction and prevention in the context of other 
diseases where multiple genetic risk factors interact with environmental risk factors to 
drive disease development. 
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Tables 
Table 1. Interview questions for individuals who underwent biomarker testing for RA and had a 
positive test result, but no diagnosis of any inflammatory joint disease.  
 
Can you please tell me what you already know about RA? About which other issues would you like 
to be informed? 
Promts: 
What do you think the causes of RA could be?  
What do you think the risks factors for RA are?  
Tell me about how serious you think RA is?  
How would you know you had RA, for example, what symptoms would you expect?  
What would be the impact of RA on your life? 
Do you think you would be able to control RA yourself?  
Do you think there are treatments available that would effectively treat RA? 
Do you ever worry about the possibility of developing RA in the future? 
What would you think if you were told that you could have a test that would tell you how likely you 
were to develop RA? 
Promts: 
What sort of information should this test give you?  
When do you think would be the right time to get this information?  
How would you feel about a test telling you that you could develop RA in the future?  
In what ways do you think it would be helpful to know your chances of developing RA? 
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What would your concerns be if you knew what your risk of developing RA was? 
What kind of tests do you think people might be able to do to work out whether or not you might 
develop RA (test that are available now and tests that might become available in the future)? 
Various tests can currently be done, and various tests are currently being developed to predict the 
development of RA. What are your thoughts about: 
1. Blood tests looking at biomarkers, molecules in the blood  
2. Blood tests looking at genes 
3. Tests involving scanning the joints with either an ultrasound or MRI 
4. Tests involving taking tissue out of a joint (synovial biopsy) or elsewhere (e.g. lymph nodes)  
What are your thoughts about taking medicines to reduce the risk of RA developing in the future?  
What are your thoughts about changing your lifestyle (e.g. stop smoking, more exercise, change 
diet) to reduce the risk of developing RA in the future? 
Note. For using the questions in Austria and Germany, the interview questions were translated from English 
into German and translated back to English, blinded for the original wording of the questions, by a member 
of the Austrian research team using a forward-backward approach (33).  
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Table 2. Demographic data of the participants 
 
Demographic data 
Asymptomatic 
participants (n=10) 
Symptomatic 
participants (n=24) 
Total 
Number of participants/percent (%) 10 (29) 24 (71) 34 (100) 
Number of women (%) 7 (70) 19 (79) 26 (76) 
Mean age in years (±SD) 61.7 (±9.6) 48.6 (±14.4)  52.4 (±14.4) 
Age in years min/max 51 to 81 18 to 76 18 to 81 
Positive family history of RA (%) 1 (10) 9 (37.5) 10 (29.4) 
Number of participants who did not 
smoke at the time of the interview (%) 
9 (90) 19 (79) 28 (82) 
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Table 3. Qualitative coding scheme, corresponding information and education needs, and the 
related sections of the Arthritis Educational Needs Assessment Tool (ENAT). The ENAT was 
used as a frame of reference for identifying information and education needs. 
 
 
Higher-level themes Codes 
Information and education needs of individuals 
who undergo predictive testing and have a positive 
test result 
Related section of 
the ENAT 
4 37   
Decision making 
around whether 
to undergo initial 
predictive testing 
 Gain information about the 
own health 
 Assurance about causes for 
symptoms 
 Receive confirmation that 
something is wrong 
 For research purposes only  
Information on different reasons for undergoing 
predictive testing 
Reasons for repeating the biomarker testing: future 
options might include regular (annual) 
tests/assessments for research purposes, but also to 
improve future prediction. Otherwise individuals 
should be advised to come once synovial swellings 
develop, telephone helplines might also be an 
option. 
Predictive testing 
is so far not part 
of the ENAT 
Section related to 
support from 
other people 
Willingness to consider 
further predictive tests  
 Positive attitude towards 
the previous test 
 Negative attitude towards 
the previous test 
 Right time point - as early 
as possible 
 Not the right time point 
 Agree to biomarker test 
 Refuse biomarker test 
 Agree to genetic testing 
 Refuse genetic testing 
 Agree to ultrasound or MRI 
 Agree to ultrasound or MRI 
only with symptoms 
 Refuse ultrasound or MRI 
 Agree to synovial biopsy 
 Agree to synovial biopsy 
only with symptoms 
 Refuse synovial biopsy 
Information on evidence and availability of potential 
additional predictive tests methods 
Additional information about advantages and 
potential side effects, as well as validity of the 
various tests (statement to which extend a test 
method is diagnostically conclusive) 
Predictive testing 
is so far not part 
of the ENAT 
Section related to 
support from 
other people 
Willingness to consider 
preventive 
interventions, including 
medication 
 Agree to preventive 
medication 
 Strictly reject preventive 
medication 
 Fear of side effects 
 Critical view on preventive 
medication 
 More information needed 
to make a decision 
 Modify one's life/changing 
lifestyle 
Information about the lack of current availability of 
preventive medication for RA and potential future 
options  
Section on 
treatments one 
may be receive 
from health 
professionals 
(including 
medication) 
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Higher-level themes Codes 
Information and education needs of individuals 
who undergo predictive testing and have a positive 
test result 
Related section of 
the ENAT 
Varying reactions after 
receiving a positive test 
result 
 Be shocked/be anxious 
 Be surprised 
 Feel vindicated 
 Feel weak and powerless 
 Get worried 
 Stay calm 
 Reconsider one’s life 
 Ignore the positive test 
result 
 Uncertainty due to lack of 
information 
 Difficulties in talking about 
being at risk with others, 
including family and friends 
 Criticism on unspecific test 
results 
 Agree on monitoring 
 See monitoring critical 
Knowledge about RA 
Probability of risk to develop RA based on the test 
results 
How and where to receive support to minimize 
psychological stress 
 
Information about healthy life-styles in relation to 
the onset of RA 
When to see a rheumatologist based on symptoms 
Whom to contact when synovial joint swelling occurs 
Monitoring on a regular basis 
 
 
How to inform family members and significant 
others in easy words about being a person at risk of 
developing RA 
Section related to 
disease processes 
of arthritis 
Section related to 
feelings 
 
Sections related 
to treatments one 
may be doing for 
oneself, 
movement and  
managing pain 
 
Sections related 
to treatments one 
may be receiving 
from health 
professionals and 
support from 
other people 
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Table 4. Additional quotes related to the four higher-level themes of the qualitative data 
analysis 
 
Higher-level theme 1: Decision making around whether to undergo initial predictive testing Corresponding codes 
That was during a preventive health check-up and I thought, it’s good to do research in this field 
and it’s definitely something useful and then I took part. (No. 3, female age 67, asymptomatic, 
Austria) 
 
I thought, maybe this will help other people. Even if I am not affected, it might help somebody else. 
(No.22, female, age 69, asymptomatic, Vienna) 
 
Yes, I have pain in the joints regularly and that’s why it was interesting to me to find out the results. 
I think it was just confirmation that my feeling wasn’t just made up of thin air. (No. 24, female, age 
47, arthralgia, Austria) 
 
You’re never happy about a disease, but I consider clarification as important. Every person thinks 
about it differently but I always would like to have the facts because I can then adapt myself more 
easily. I find it much more reassuring than the lack of knowledge. (No. 19, female, age 49, 
arthralgia, Germany) 
For research purposes 
only 
 
 
For research purposes 
only 
 
Assurance about 
causes for symptoms 
 
 
 
Assurance about 
causes for symptoms 
Higher-level theme 2: Willingness to consider further predictive tests Corresponding codes 
It’s not one of my hobbies, that’s not harmless, invasive and probably painful, extracting tissue is 
more substantial and I would only have that done if I really had problems. (No. 25, male, age 57, 
asymptomatic, Austria – about synovial biopsy) 
 
I don’t want that! It is going into too much detail - in my genes - I cannot imagine that I would like 
this at the moment. (No. 31, female, age 52, arthralgia, Germany – about genetic testing) 
 
Refuse synovial biopsy 
 
 
Refuse genetic testing 
Higher-level theme 3: Willingness to consider preventive interventions, including medication Corresponding codes 
I would not do that, simply from my point of view. I would try other possibilities first, as I’ve 
mentioned life style. Not even a 100 percent chance of developing rheumatoid arthritis within the 
next 5 years, would lead me to take prophylactic medicine. Then I’d have to put preventive pills, 
against everything, in my cereal bowl in the morning already instead of breakfast; no, I would never 
agree to take preventive medication. (...) It’s easy for me to say so, as I’m not in any pain. Maybe, if 
I will have any pain in three years, I would then think, if I only had taken preventive medication 
earlier! But you can’t insure yourself against everything and you can’t eat pills against everything! 
(No. 2, female, age 66, asymptomatic, Austria) 
 
Only under the condition that a person would receive the necessary information to be able to decide 
whether to take a preventive medicine. (No. 26, female, age 43, arthralgia, UK) 
 
 
 
Strictly reject 
preventive medication 
 
 
 
More information 
needed to make a 
decision 
Higher-level theme 4: Varying reactions after receiving a positive test result Corresponding codes 
It’s like looking into a crystal ball [of a fortune teller] and saying to you, ‘Oh, (…) you could 
potentially get rheumatoid arthritis.’ And then, always, I have images of people in my mind who 
have deformities and disabilities. (No. 26, female, age 43, arthralgia, UK) 
 
I was quite shocked to find out that I had these cells [patient’s interpretation after having been told 
they had a positive autoantibody test] , to tell you the truth. How am I gonna, you know, carry on 
with work, you know, things like that and, you know, my future. (No. 11, male, age 50, arthralgia, 
UK).  
 
I know that I have those positive factors. That was a coincidence but it doesn’t worry me at all. I 
cannot change it anyway. (No. 3, female, age 67, asymptomatic, Austria) 
Uncertainty due to lack 
of information 
 
 
 
Be shocked/be anxious 
 
 
 
Stay calm 
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Higher-level theme 1: Decision making around whether to undergo initial predictive testing Corresponding codes 
 
Well, changing life style means changing diet, difficult, because changing your diet, abstaining from 
certain food that you like to eat, means reducing your quality of life. I personally don’t agree with 
that, I’m definitely not going on a diet because of a disease I don’t have at the moment! But I 
certainly would if I had any symptoms. (No. 25, male, age 57, asymptomatic, Austria) 
 
Ignore the positive test 
result 
Note. While themes two and three were strongly related to the interview questions, the first and last higher-level theme 
was brought up by the participants in addition to already raised topics by the researchers. 
 
